Ocular Therapeutix develops eye treatments, including AXPAXLI, an investigational drug in trials for eye diseases, and sells DEXTENZA. It last closed at $5.57 on Nov 20, down 4.95% on the day. The next earnings report for OCUL is expected around Thu, Feb 4, 2027. For the quarter ended Sep 2026, OCUL reported EPS of -$0.42 on revenue of $12.9M, with revenue down 11.5% from a year ago. Over its last 8 reports the stock moved an average of 6.0% the session after earnings. Over the last 12 months OCUL insiders bought $461K of stock on the open market and sold $3.3M, according to SEC Form 4 filings.
AI Auto Pilots
Is OCUL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OCUL.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on OCULStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
OCUL · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 17% below its 20 day and 34% below its 50 day average. It is 59% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the 52 week low at $5.54, and the nearest resistance the Pivot at $5.69.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.8%/day
Key levels
$16.4452 week high+195.2%
$8.83200 day average+58.5%
$8.67100 day average+55.7%
$7.4950 day average+34.5%
$7.24Swing high (Nov 5)+30.0%
$6.5220 day average+17.1%
$5.83Pivot R1+4.7%
$5.69Pivot+2.2%
$5.57Last close
$5.5452 week low−0.5%
$5.42Pivot S1−2.7%
Indicators
RSI (14)
30.59
Weak, oversold below 30
Neutral
MACD
-0.45
Below its signal line
Bearish
Stochastic
5.5
Near the bottom of its range
Oversold
ADX (14)
45.1
Strong downtrend
Williams %R
-98.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-163.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.5%
Change over 10 sessions
Bearish
ATR (14)
$0.44
Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 20.7%/day
Key levels
$16.4452 week high+195.2%
$8.83200 day average+58.5%
$8.67100 day average+55.7%
$7.4950 day average+34.5%
$7.24Swing high (Nov 5)+30.0%
$6.5220 day average+17.1%
$5.83Pivot R1+4.7%
$5.69Pivot+2.2%
$5.57Last close
$5.5452 week low−0.5%
$5.42Pivot S1−2.7%
Indicators
RSI (14)
33.61
Weak, oversold below 30
Neutral
MACD
-0.91
Below its signal line
Bearish
Stochastic
4.9
Near the bottom of its range
Oversold
ADX (14)
18.6
No clear trend
Williams %R
-99.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-127.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−46.9%
Change over 10 sessions
Bearish
ATR (14)
$1.15
Typical daily range, 20.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCUL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OCUL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow OCUL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for OCULHow many large options trades hit OCUL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in OCUL in the last 90 days.
From SEC Form 4 filings by OCUL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCUL is in one of them and how their past OCUL trades turned out.
Ocular Therapeutix is a biopharmaceutical company based in Bedford, Massachusetts, that develops and sells treatments for eye conditions. Its lead investigational product, AXPAXLI, is a drug delivered into the eye through a gel that dissolves over time, and it is being tested for wet macular degeneration and diabetic retinal disease. The company also sells DEXTENZA, an FDA-approved insert used to treat eye pain and inflammation after surgery and itching from allergic conjunctivitis.